Publications

Publications 2016

PAPERS PUBLISHED IN 2016

 


INTERACTION BETWEEN BETA-CATENIN AND EGFR EXPRESSION BY IMMUNOHISTOCHEMISTRY IDENTIFIES PROGNOSTIC SUBGROUPS IN EARLY HIGH-RISK TRIPLE NEGATIVE BREAST CANCER.  

Sotirios Lakis, Stefanos Dimoudis, Vassiliki Kotoula, Zoi Alexopoulou, Ioannis Kostopoulos, Triantafyllia Koletsa, Mattheos Bobos, Eleni Timotheadou, Irene Papaspirou, Ioannis Efstratiou, Gerasimos Aravantinos, Vasilios Karavasilis, Flora Zagouri, Helen Gogas, Evangelia Razis, George Pentheroudakis, Christos Christodoulou, Dimitrios Pectasides, George Fountzilas

Anticancer Res. 2016 May;36(5):2365-78.

Breast


SAFETY AND TOLERABILITY OF ANTHRACYCLINE-CONTAINING ADJUVANT CHEMOTHERAPY IN ELDERLY HIGH-RISK BREAST CANCER PATIENTS

Vasilios Karavasilis, Christos Papadimitriou, Helen Gogas, George Kouvatseas, George Pentheroudakis, Angelos Koutras, Christos Christodoulou, Dimitrios Bafaloukos, Epaminontas Samantas, Nikolaos Pisanidis, Pavlos Papakostas, Gerasimos Aravantinos, Charisios Karanikiotis, Paris Kosmidis, Dimitrios Pectasides, Meletios-Athanassios Dimopoulos, George Fountzilas

Clin Breast Cancer2016 Aug;16(4):291-298.e3. doi: 10.1016/j.clbc.2015.12.001. Epub 2015 Dec 17.

Breast


GENES ASSOCIATED WITH HISTOPATHOLOGIC FEATURES OF TRIPLE NEGATIVE BREAST TUMORS PREDICT MOLECULAR SUBTYPES

Purrington KS, Visscher DW, Wang C, Yannoukakos D, Hamann U, Nevanlinna H, Cox A, Giles GG, Eckel-Passow JE, Lakis S, Kotoula V, Fountzilas G, Kabisch M, Rüdiger T, Heikkilä P, Blomqvist C, Cross SS, Southey MC, Olson JE, Gilbert J, Deming-Halverson S, Kosma VM, Clarke C, Scott R, Jones JL, Zheng W, Mannermaa A; Jane Carpenter for ABCTC Investigators, Eccles DM, Vachon CM, Couch FJ.

Breast Cancer Res Treat. 2016 May;157(1):117-31. doi: 10.1007/s10549-016-3775-2. Epub 2016 Apr 15.

Breast


COMPARISON OF THE ABILITY OF DIFFERENT CLINICAL TREATMENT SCORES TO ESTIMATE PROGNOSIS IN HIGH-RISK EARLY BREAST CANCER PATIENTS: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

Flora Stavridi, Konstantine T. Kalogeras, Kyriaki Pliarchopoulou, Ralph M. Wirtz, Zoi Alexopoulou, Flora Zagouri, Elke Veltrup, Eleni Timotheadou, Helen Gogas, Angelos Koutras, Georgios Lazaridis, Christos Christodoulou, George Pentheroudakis, Apostolos Laskarakis, Petroula Arapantoni-Dadioti, Anna Batistatou, Maria Sotiropoulou, Gerasimos Aravantinos, Pavlos Papakostas, Paris Kosmidis, Dimitrios Pectasides, George Fountzilas

PLoS One. 2016 Oct 3;11(10):e0164013. doi: 10.1371/journal.pone.0164013.

Breast


MYC COPY GAIN, CHROMOSOMAL INSTABILITY AND PI3K ACTIVATION AS POTENTIAL MARKERS OF UNFAVOURABLE OUTCOME IN TRASTUZUMAB-TREATED PATIENTS WITH METASTATIC BREAST CANCER

Helen Gogas, Vassiliki Kotoula, Zoi Alexopoulou, Christos Christodoulou, Ioannis Kostopoulos, Mattheos Bobos, Georgia Raptou, Elpida Charalambous, Eleftheria Tsolaki, Ioannis Xanthakis, George Pentheroudakis, Angelos Koutras, Dimitrios Bafaloukos, Pavlos Papakostas, Gerasimos Aravantinos, Amanda Psyrri, Kalliopi Petraki, Dimitrios Pectasides, George Fountzilas

J Transl Med. 2016 May 17;14(1):136. doi: 10.1186/s12967-016-0883-z.

Breast


TP53 MUTATIONS AND PROTEIN IMMUNOPOSITIVITY MAY PREDICT FOR POOR OUTCOME BUT ALSO FOR TRASTUZUMAB BENEFIT IN PATIENTS WITH EARLY BREAST CANCER TREATED IN THE ADJUVANT SETTING

Fountzilas G, Giannoulatou E, Alexopoulou Z, Zagouri F, Timotheadou E, Papadopoulou K, Lakis S, Bobos M, Poulios C, Sotiropoulou M, Lyberopoulou A, Gogas H, Pentheroudakis G, Pectasides D, Koutras A, Christodoulou C, Papandreou C, Samantas E, Papakostas P, Kosmidis P, Bafaloukos D, Karanikiotis C, Dimopoulos MA, Kotoula V.

Oncotarget. 2016 May 31;7(22):32731-53. doi: 10.18632/oncotarget.9022.

Breast


TUMORS WITH HIGH-DENSITY TUMOR INFILTRATING LYMPHOCYTES CONSTITUTE A FAVORABLE ENTITY IN BREAST CANCER: A POOLED ANALYSIS OF FOUR PROSPECTIVE ADJUVANT TRIALS.

Kotoula VChatzopoulos KLakis SAlexopoulou ZTimotheadou EZagouri FPentheroudakis GGogas HGalani EEfstratiou IZaramboukas TKoutras AAravantinos GSamantas EPsyrri AKourea HBobos MPapakostas PKosmidis PPectasides DFountzilas G

Oncotarget. 2016 Jan 26;7(4):5074-87. doi: 10.18632/oncotarget.6231.

Breast


EFFECTS OF TP53 AND PIK3CA MUTATIONS IN EARLY BREAST CANCER: A MATTER OF CO-MUTATION AND TUMOR INFILTRATING LYMPHOCYTES

Vassiliki Kotoula, Vasilios Karavasilis, Flora Zagouri, George Kouvatseas, Eleni Giannoulatou, Helen Gogas, Sotiris Lakis, George Pentheroudakis, Mattheos Bobos, Kyriaki Papadopoulou, Eleftheria Tsolaki, Dimitrios Pectasides, Georgios Lazaridis, Angelos Koutras, Gerasimos Aravantinos, Christos Christodoulou, Pavlos Papakostas, Christos Markopoulos, George Zografos, Christos Papandreou, George Fountzilas

Breast Cancer Res Treat. 2016 Jul;158(2):307-21. doi: 10.1007/s10549-016-3883-z. Epub 2016 Jul 1.

Breast


MALE BREAST CANCER IN BRCA1 AND BRCA2 MUTATION CARRIERS: PATHOLOGY DATA FROM THE CONSORTIUM OF INVESTIGATORS OF MODIFIERS OF BRCA1/2.

Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL,….Garber J, Fostira F, Fountzilas G, Chenevix-Trench G, Antoniou AC, Ottini L.

Breast Cancer Res. 2016 Feb 9;18(1):15. doi: 10.1186/s13058-016-0671-y.

Breast


TUMOR INFILTRATING LYMPHOCYTES AFFECT THE OUTCOME OF PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER IN COMBINATION WITH MUTATED AMINO ACID CLASSES.

Kotoula V, Lakis S, Vlachos IS, Giannoulatou E, Zagouri F, Alexopoulou Z, Gogas H, Pectasides D, Aravantinos G, Efstratiou I, Pentheroudakis G, Papadopoulou K, Chatzopoulos K, Papakostas P, Sotiropoulou M, Nicolaou I, Razis E, Psyrri A, Kosmidis P, Papadimitriou C, Fountzilas G.

PLoS One. 2016 Sep 29;11(9):e0163138. doi: 10.1371/journal.pone.0163138. eCollection 2016.

Breast


HAPLOTYPE ANALYSIS REVEALS THAT THE RECURRENT BRCA1 DELETION OF EXONS 23 AND 24 IS A GREEK FOUNDER MUTATION.

Apostolou P, Pertesi M, Aleporou-Marinou V, Dimitrakakis C, Papadimitriou C, Razis E, Christodoulou C, Fountzilas G, Yannoukakos D, Konstantopoulou I, Fostira F.

Clin Genet2017 Mar;91(3):482-487.doi: 10.1111/cge.12824. Epub 2016 Aug 22.

Breast


DISEASE EVOLUTION AND HETEROGENEITY IN BILATERAL BREAST CANCER.

Fountzilas E, Kotoula V, Zagouri F, Giannoulatou E, Kouvatseas G, Pentheroudakis G, Koletsa T, Bobos M, Papadopoulou K, Samantas E, Demiri E, Miliaras S, Christodoulou C, Chrisafi S, Razis E, Fostira F, Pectasides D, Zografos G, Fountzilas G.

Am J Cancer Res. 2016 Nov 1;6(11):2611-2630

Breast


HER FAMILY PROTEIN EXPRESSION IN A GREEK POPULATION WITH GASTRIC CANCER. A RETROSPECTIVE HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

T. Makatsoris, A.C. Tsamandas, A. Strimpakos, Z. Alexopoulou, D. Dionysopoulos, S. Pervana, A. Konstantara, P. Papakostas, E. Samantas, G. Rallis, A. Dimou, G. Pentheroudakis, K. Papaparaskeva, A. Psyrri, K.T. Kalogeras, K. Syrigos, C.D. Scopa, G. Fountzilas

Anticancer Research 36: 1581-1590 (2016)

GI


EVALUATION OF CPG ISLAND METHYLATOR PHENOTYPE AS A BIOMARKER IN COLORECTAL CANCER TREATED WITH ADJUVANT OXALIPLATIN

Cohen SA, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, Grady WM.

Clin Colorectal Cancer. 2016 Jun;15(2):164-9. doi: 10.1016/j.clcc.2015.10.005.

GI


EXPRESSION PATTERNS OF GROWTH AND SURVIVAL GENES WITH PROGNOSTIC IMPLICATIONS IN ADVANCED PANCREATIC CANCER.

Pectasides D, Kotoula V, Papaxoinis G, Alexopoulou Z, Dervenis C, Samantas E, Papaparaskeva K, Charalambous E, Gkakou C, Agalianos C, Kalogeras KT, Pentheroudakis G, Fountzilas G.

Anticancer Res. 2016 Dec;36(12):6347-6356.

GI


EVALUATION OF PD-L1 EXPRESSION AND ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTES IN LARYNGEAL SQUAMOUS CELL CARCINOMA

Vassilakopoulou MAvgeris MVelcheti VKotoula VRampias T4, Chatzopoulos KPerisanidis CKontos CKGiotakis AIScorilas ARimm DSasaki CFountzilas GPsyrri A

Clin Cancer Res. 2016 Feb 1;22(3):704-13. doi: 10.1158/1078-0432.CCR-15-1543.

H&N


LESSONS FROM THE PAST: LONG-TERM SAFETY AND SURVIVAL OUTCOMES OF A PREMATURELY TERMINATED RANDOMIZED CONTROLLED TRIAL OF PROPHYLACTIC VERSUS HEMOGLOBIN-BASED ERYTHROPOIETIN ADMINISTRATION IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA.

Giannis Mountzios, Gerasimos Aravantinos, Zoi Alexopoulou, Eleni Timotheadou, Fotini Matsiakou, Christos Christodoulou, Konstantinos Laschos, Eleni Galani, Angelos Koutras, Dimitrios Bafaloukos, Helena Linardou, Dimitrios Pectasides, Ioannis Varthalitis, Pavlos Papakostas, Haralambos P. Kalofonos and George Fountzilas

Mol Clin Oncol. 2016 Feb;4(2):211-220.

Supportive Care


NOVEL THERAPIES FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG.

Koutsoukos K, Mountzios G.

Future Oncol. 2016 Mar;12(5):659-67.

Lung


THERAPIES IN THE PIPELINE FOR SMALL-CELL LUNG CANCER.

Romanidou O, Imbimbo M, Mountzios G, Abidin A, Morgillo F, Califano R.

Br Med Bull. 2016 Sep;119(1):37-48.

Lung


Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

Califano R, Romanidou O, Mountzios G, Landi L, Cappuzzo F, Blackhall F.

Drugs. 2016 May;76(8):831-40. 

Lung


A POOLED ANALYSIS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER AND THE ROLE OF PD-L1 AS A PREDICTIVE BIOMARKER.

Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Tsiatas M, Oliveira P, Castelo-Branco P, Mountzios G, de Mello RA.

Immunotherapy2016 Sep;8(9):1011-9. doi: 10.2217/imt-2016-0032

Lung


NON-SMALL CELL LUNG CANCER (NSCLC) AND CENTRAL NERVOUS SYSTEM (CNS) METASTASES: ROLE OF TYROSINE KINASE INHIBITORS (TKIS) AND EVIDENCE IN FAVOR OR AGAINST THEIR USE WITH CONCURRENT CRANIAL RADIOTHERAPY

Panagiota Economopoulou,  Giannis Mountzios

Transl Lung Cancer Res. 2016 Dec;5(6):588-598. doi: 10.21037/tlcr.2016.12.06.PMID: 28149754

Lung


THE IMPACT OF PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY ON THE AUTONOMOUS NERVOUS SYSTEM OF PATIENTS WITH OVARIAN CANCER.

Emmanouil Dermitzakis; Vasilios K. Kimiskidis; George Lazaridis; Zoi Alexopoulou; Eleni Timotheadou; Alexandros Papanikolaou; Ourania Romanidou; George Georgiadis; Konstantine T Kalogeras; Iakovos Tsiptsios; Basil Tarlatzis; George Fountzilas

BMC Neurol. 2016 Oct 1;16(1):190.  doi: 10.1186/s12883-016-0710-4.

Gynecological


PROGNOSTIC AND PREDICTIVE EFFECTS OF PRIMARY VERSUS SECONDARY PLATINUM RESISTANCE FOR BEVACIZUMAB TREATMENT FOR PLATINUM-RESISTANT OVARIAN CANCER IN THE AURELIA TRIAL.

Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E.

Ann Oncol. 2016 Sep;27(9):1733-9. doi: 10.1093/annonc/mdw236

Gynecological


INTRAVENOUS HIGH-DOSE INTERFERON WITH OR WITHOUT MAINTENANCE TREATMENT IN MELANOMA AT HIGH RISK OF RECURRENCE: META-ANALYSIS OF THREE TRIALS.

Malczewski A, Marshall A, Payne MJ, Mao L, Bafaloukos D, Si L, Pectasides D, Fountzilas G, Guo J, Gogas H, Middleton MR.

Cancer Med. 2016 Jan;5(1):17-23. doi: 10.1002/cam4.563. Epub 2015 Dec 8

Melanoma


POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME WITH CONCURRENT NEPHROTIC SYNDROME IN A PATIENT TREATED WITH PAZOPANIB FOR METASTATIC RENAL CELL CARCINOMA: CASE REPORT AND REVIEW OF THE LITERATURE.

Miaris N, Maltezou M, Papaxoinis G, Visvikis A,SamantasE.

Clin Genitourin Cancer. Published online 2016. doi:10.1016/j.clgc.2016.08.005

Genitourinary


 

ATM SPECIAL ISSUE

 


OVERVIEW OF ADVANCES IN CANCER IMMUNOTHERAPY.

Kotoula V, Fountzilas G.

Ann Transl Med. 2016 jul;4(14):260. doi: 10.21037/atm.2016.07.09


HARNESSING THE IMMUNE SYSTEM TO IMPROVE CANCER THERAPY.

Papaioannou NE, Beniata OVVitsos PTsitsilonis OSamara P

Ann Transl Med. 2016 Jul;4(14):261. doi: 10.21037/atm.2016.04.01


THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER PERSPECTIVE ON DESIGNING CLINICAL TRIALS WITH IMMUNE THERAPEUTICS.

Menis J, Litière S, Tryfonidis K, Golfinopoulos V.

Ann Transl Med. 2016 Jul;4(14):267. doi: 10.21037/atm.2016.06.19. Review


OPTIMIZED TUMOR CRYPTIC PEPTIDES: THE BASIS FOR UNIVERSAL NEO-ANTIGEN-LIKE TUMOR VACCINES.

Menez-Jamet J, Gallou C, Rougeot A, Kosmatopoulos K.

Ann Transl Med. 2016 Jul;4(14):266. doi: 10.21037/atm.2016.05.15. Review


MELANOMA IMMUNOTHERAPY DOMINATES THE FIELD.

Diamantopoulos P, Gogas H.

Ann Transl Med. 2016 Jul;4(14):269. doi: 10.21037/atm.2016.06.32. Review


THE DUAL ROLE OF COMPLEMENT IN CANCER AND ITS IMPLICATION IN ANTI-TUMOR THERAPY.

Kourtzelis I, Rafail S.

Ann Transl Med. 2016 Jul;4(14):265. doi: 10.21037/atm.2016.06.26. Review


NEOANTIGEN-BASED CANCER IMMUNOTHERAPY.

Bobisse S, Foukas PG, Coukos G, Harari A.

Ann Transl Med. 2016 Jul;4(14):262. doi: 10.21037/atm.2016.06.17. Review


THE SIGNIFICANCE OF TUMOR-ASSOCIATED IMMUNE RESPONSE IN MOLECULAR TAXONOMY, PROGNOSIS AND THERAPY OF COLORECTAL CANCER PATIENTS.

Nearchou A, Pentheroudakis G.

Ann Transl Med. 2016 Jul;4(14):271. doi: 10.21037/atm.2016.05.54. Review


FUTURE PERSPECTIVES IN CANCER IMMUNOTHERAPY.

Tsiatas M, Mountzios G, Curigliano G.

Ann Transl Med. 2016 Jul;4(14):273. doi: 10.21037/atm.2016.07.14


TOXICITY MANAGEMENT OF IMMUNOTHERAPY FOR PATIENTS WITH METASTATIC MELANOMA.

Linardou H, Gogas H.

Ann Transl Med. 2016 Jul;4(14):272. doi: 10.21037/atm.2016.07.10. Review


DNA DAMAGE, TUMOR MUTATIONAL LOAD AND THEIR IMPACT ON IMMUNE RESPONSES AGAINST CANCER.

Liontos M, Anastasiou I, Bamias A, Dimopoulos MA.

Ann Transl Med. 2016 Jul;4(14):264. doi: 10.21037/atm.2016.07.11. Review


TOWARDS TUMOR IMMUNODIAGNOSTICS.

Kourea H, Kotoula V.

Ann Transl Med. 2016 Jul;4(14):263. doi: 10.21037/atm.2016.07.07. Review


IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER: THE CLINICAL IMPACT OF IMMUNE RESPONSE AND TARGETING.

Mountzios G, Linardou H, Kosmidis P.

Ann Transl Med. 2016 Jul;4(14):268. doi: 10.21037/atm.2016.06.24. Review